Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Beats Revenue Estimates
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of -438.92% and +6.30%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?